Schjesvold, F., P.M. Voorhees, M.A. Dimopoulos, Y.C. Cohen, V. Hungria, I. Sandhu, J. Lindsay, R.I. Baker, K. Suzuki, H. Kosugi, M-D. Levin, M. Beksac, K. Stockerl-Goldstein, H. Magen, A. Oriol, G. Mikala, G. Garate, K. Theunissen, I. Spicka, A.K. Mylin, S. Hallam, S. Bringhen, K. Uttervall, B. Pula, A.M. Khan, E. Medvedova, J.C. Ye, A.J. Cowan, Ph. Moreau, M-V. Mateos, H. Goldschmidt, D. Vieyra, A. Raval, L. Sha, L. Li, E. Rousseau, R.M. Dennis, R.L. Carson, and S.V. Rajkumar. 2026. “B09 | DARATUMUMAB MONOTHERAPY VS. ACTIVE MONITORING IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA: "AQUILA" OUTCOMES BASED ON MAYO 2018/IMWG 2020 RISK STRATIFICATION, IMWG 2020 PLUS CYTOGENETIC CRITERIA, AND AGE”. Haematologica 111 (s2). Pavia, Italy. https://doi.org/10.3324/haematol.2026.s2.14042.